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In Brief
Dermal immature adipocytes fight against Staphylococcus aureus infection by secreting antimicrobial peptides during adipogenesis. Zhang et al. demonstrate that activation of the TGF-b pathway suppresses the adipogenic potential of dermal fibroblasts and therefore leads to an age-dependent loss of antimicrobial protection from dermal fat.
INTRODUCTION
Staphylococcus aureus (S. aureus) is responsible for the majority of skin and soft-tissue infections in humans, and MRSA (methicillin-resistant S. aureus) infections over the past two decades were responsible for more deaths in the United States than any other pathogen (Klein et al., 2007; Miller and Cho, 2011) . It is difficult to treat S. aureus infections because of its evolved resistance to common antibiotics; therefore, a better understanding of skin host defense mechanisms against S. aureus is acutely needed for developing strategies to combat this important public health problem.
Skin provides a physical and immunological barrier protecting internal tissues from external insults. Dermal white adipose tissue (dWAT) is the deepest barrier of the skin and an understudied fat depot compared with inguinal white adipose tissue (iWAT) and epididymal white adipose tissue (eWAT) (Zwick et al., 2018) . Until recently, dWAT was thought to function merely as an energy reservoir and a thermo-insulating layer. Recent studies, however, have revealed that dWAT also plays active roles in various physiological and pathological processes, such as the regeneration of hair follicles (Festa et al., 2011) , wound healing (Plikus et al., 2017; Schmidt and Horsley, 2013) , thermogenesis (Kasza et al., 2014) , skin fibrosis (Marangoni et al., 2015) , and protection against skin infection (Zhang et al., 2015) . dWAT is produced by a subpopulation of dermal fibroblasts (dFBs). dFBs are a major skin cell type that has considerable functional diversity (Philippeos et al., 2018; Tabib et al., 2018) . The reticular dermis contains dFBs with adipocyte progenitor properties, and these cells can commit to preadipocytes (pAds) and differentiate into adipocytes (ADs) upon stimulation (Driskell et al., 2013; Festa et al., 2011; Schmidt and Horsley, 2013; Zhang et al., 2015) .
S. aureus skin infection triggers the rapid and localized differentiation of pAds to ADs, and we refer to this process as reactive adipogenesis. Reactive adipogenesis is characterized by the proliferation of adipocyte progenitor cells expressing preadipocyte factor 1 (PREF1) and is followed by their differentiation into immature ADs (Zhang et al., 2015) . During this process, cathelicidin antimicrobial peptide (Camp) is abundantly expressed during the immature AD stage of differentiation. This expression of Camp is necessary to limit bacterial spread because the inhibition of this adipogenic-antimicrobial function of immature ADs leads to increased susceptibility to S. aureus infection (Zhang et al., 2015) .
In this study, we sought to better understand the regulation of reactive adipogenesis in skin innate immunity. To explore this Pdgfra-cre mice (n = 6 per group).
(legend continued on next page) question, we investigated changes in adipogenic function of dFBs during embryonic and adult development in mouse and human skin. A decrease in the capacity of dFBs to differentiate into adipocytes and express cathelicidin was observed to occur after birth and during the adult period of life. Furthermore, transforming growth factor beta (TGF-b) was identified to induce the loss of adipogenic potential and antimicrobial function of dFBs. These results uncover a previously unknown mechanism that impairs innate immune defense of the skin. Adipoq-cre mice became significantly more susceptible to S. aureus infection than wild-type (WT) littermate controls . These results reinforce the conclusion that cathelicidin derived from cells of the adipocyte lineage plays a role in defense against S. aureus infection.
RESULTS

Dermal
In general, innate immune defense is maximal in late fetal and early postnatal life and declines with age (Futata et al., 2012; Georgountzou and Papadopoulos, 2017; Shaw et al., 2013 ). An age-dependent decrease in the ability of skin to clear bacteria was evident by increased bacterial colony-forming units (CFU) in the infection edge area with advancing age (Figures 1D and S1I) . To understand the contribution of adipogenesis to this loss of innate immune defense, we next examined the expression of cathelicidin in the cells of the adipocyte lineage during aging. A progressive loss of the capacity of S. aureus to trigger reactive adipogenesis was observed with advancing age, as measured by lesser staining of cathelicidin ( Figure 1E ) and lower expression of Pref1 and Camp mRNA ( Figures S1J and 1F ) in dWAT at sites of infection. Loss of dermal reactive adipogenesis in response to S. aureus correlated with an age-dependent increase in the mRNA expression of Spp1, a pro-fibrotic marker ( Figure 1F ).
Next, we established a flow-cytometry method to define dFB cell populations that are activated upon S. aureus infection. Adipogenic dFBs were gated as CD31 À ;CD45 À ;PDGFRA + ;THY1 hi cells (Chia et al., 2016; Rivera-Gonzalez et al., 2016 Figures 1G, 1H , and S1K). This suggested that reactive adipogenesis was restricted to THY1 hi dFBs. To determine whether age-related loss of reactive adipogenesis was associated with the loss of THY1 hi dFBs, we analyzed THY1 expression in PDGFRA + dFBs in the late embryos and in mice up to 2 years of age. Fibroblasts from eWAT were also analyzed because eWAT has been previously reported to have age-associated dysfunction in adipogenesis and increased production of pro-inflammatory cytokines and fibrotic features (Kirkland et al., 1993; Sun et al., 2013) . Flow-cytometry analyses revealed that PDGFRA + fibroblasts in eWAT progressively lost THY1 expression with advancing age (from 3 weeks, 2 months, and 1 year to 2 years old), and by 1-2 years of age, PDGFRA + fibroblasts in eWAT were mostly THY1 lo ( Figures 1I-1K ). In the skin, embryonic day 14 (E14) PDGFRA + dFBs were mostly THY1 lo (>97%) and became mostly THY1 hi (>90%) by postnatal day 1 (P1).
Similar to that in eWAT, THY1 expression in dermal PDGFRA + fibroblasts then became progressively lost during postnatal development and aging ( Figures 1I-1K ). Thus, age-related loss of THY1 expression is a common feature of PDGFRA + fibroblasts in both eWAT and skin.
Next Figures  1L, S1M , and S1N). PDGFRA + THY1 hi dFBs represented the major resident innate cell type ($75% of total dermal cells) in neonatal (P1) skin. During postnatal development (at 3 weeks (D) 3-week-old, 2-month-old, 1-year-old, or 2-year-old WT mice were infected i.d. with S. aureus, and bacteria CFU count was measured from the infection edge area (n = 4-5 per group). (E) Cathelicidin (red) and COLIV (green) immunohistochemistry staining in control or S. aureus-infected skin (representative of n = 3 per group). Nuclei were stained with DAPI (blue). Scale bars, 100 mm. (F) qRT-PCR of Camp or Spp1 expression in S. aureus-infected skin or control skin (ratio to Tbp) (n = 3-5 per group). (G) Flow-cytometry plots for gating strategies for dermal PDGFRA + THY1 hi adipocyte progenitors (representative of n = 3 per group).
(H) Flow-cytometry quantification of the geometric mean fluorescence intensity (gMFI) per group). All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Please also see Figure S1 . and 2 months of age), the decline in THY1 hi dFBs was accompanied by an increase in myeloid-derived immune cell populations. Upon aging (at 1 or 2 years of age), the THY1 hi dFB population continued to decline, as did macrophages and DCs, whereas CD45 + TCRab + cells increased both in the skin and in eWAT (Figures 1L , S1M, and S1N). Next, we characterized whether age-related changes in adipogenic dFBs correlated with changes in dermal fibrogenesis and adipogenesis. As shown in Figure 2A , whereas dWAT and the fibrogenic features (collagen staining and dermal hydroproline content) of the dermis were not developed in E14 skin, neonatal skin featured a large volume of dWAT with immature adipocytes and numerous small lipid droplets (Figures 2A, 2B , and S2A). Dermal adipocytes matured (indicated by large lipid droplets) by 3 weeks of age and were then gradually lost during adulthood and aging (from 2 months to 2 years of age) ( Figure 2A ). Loss of immature dermal fat with advancing age was also supported by an early peak at P1 in the mRNA expression of Pref1 and Camp, genes associated with early adipogenesis, and their subsequent progressive decline from postnatal development through aging ( Figures 2C and 2D ). Immunostaining for cathelicidin confirmed that it was abundantly expressed by P1 immature dermal ADs, whereas its expression was decreased in mature 3-week-old ADs and became undetectable in the 1-year-old ADs (Figure S2B) Adipoq-cre) led to a >95% and $75% reduction in Camp mRNA expression in neonatal skin, respectively ( Figure 2E ), confirming that differentiating immature ADs are the major cellular source of cathelicidin in neonatal skin. The expression of mature adipocyte markers, including Adipoq and Fabp4, peaked from 3 weeks to 2 months of age and then decreased progressively from 2 months to 2 years of age (Figures 2C and S2C) , supporting our histological observation that mature ADs were lost with age. Age-dependent loss of immature dermal fat coincided with an age-dependent gain in dermal fibrotic features, especially in the dWAT layer, as shown by collagen staining, hydroxyproline measurement, and Col1a1 mRNA expression (Figures 2A-2C and S2D ). Elastic fibers in dFBs also developed postnatally, and they became less dense in the lower dermis with advancing age ( Figure S2A ). By 2 years of age, the dermis appeared thinner and Col1a1 mRNA expression was low (Figures 2A and S2D) , and the dWAT layer became devoid of ADs and showed extensive collagen staining (Figures 2A and S2A) . Altogether, these results show that age-dependent loss of adipogenic dFBs is associated with a progressive loss of immature dermal fat and gain of fibrotic features.
To define adipogenic potential of the cells associated with the age-related changes observed in mouse skin, we isolated dFBs from skin at various ages and differentiated them into adipocytes in vitro. Whereas uncommitted E14 dFBs were only partially adipogenic, neonatal P1 dFBs were highly adipogenic, and this adipogenic potential gradually declined during postnatal development (from 3 weeks to 2 months of age) and was lost in 1-year-old dFBs ( Figure 2F ). Time-course analysis of differentiating neonatal dFBs showed that immature ADs with small lipid droplets were formed as early as post-differentiation day 2 (PD2), and by PD4$PD7, >90% of cells became mature ADs with large lipid droplets ( Figure 2G ). Gene expression analyses revealed four distinct expression kinetics: (1) Col1a1 and Thy1 mRNA expression was highest in undifferentiated cells and gradually decreased as cells converted to ADs; (2) Pdgfra, Sca1, Pref1, or Pparg1 mRNA expression was detected prior to differentiation, was further elevated on PD1$PD2, and then robustly decreased at PD4; (3) Camp expression was induced as early as PD1 and peaked around PD2; and (4) Pparg2, Adipoq, or Fabp4 mRNA expression was induced later, around PD2$PD4, and continued to increase as adipocytes matured (Figures 2H and 2I) .
Adipoq-cre dFBs showed loss of Camp expression and secretion through differentiation in vitro ( Figures S2E-S2G ), confirming that these adipose precursor cells are the major cellular source of cathelicidin. The ability of differentiating neonatal dFBs to express Camp and Pparg2 mRNA (Figures 2J and S2H) and to secrete cathelicidin protein into conditioned medium ( Figures S2I and S2J ) was progressively lost in dFBs isolated from 3-week-old, 2-month-old, and 1-year-old skin. In contrast, adult dFBs produced higher Col1a1 mRNA expression during differentiation than neonatal dFBs ( Figure 2J ), suggesting that decreased adipogenic function is accompanied by increased fibrogenic function in adult dFBs. Functionally, the supernatant from differentiating P1 dFBs potently inhibited the growth of S. aureus (SA113 and USA300) ( Figure 2K ), whereas the age-related decline in antimicrobial protein expression correlated with decreased capacity of differentiating dFBs to inhibit the growth of S. aureus (Figures S2L and All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Scale bars, 100 mm. Please also see Figure S2 . S2M). Altogether, these data show a loss of immature dermal fat and that the adipogenic-antimicrobial function of dFBs occurs with age.
Activation of the TGF-b Pathway Is Associated with the Loss of Antimicrobial Function of dFBs
To better understand the change in the antimicrobial and adipogenic functions of dFBs, we profiled the transcriptomes of primary dFBs isolated at different ages by RNA sequencing (RNA-seq). Because fibroblast populations become heterogeneous during postnatal development (Driskell et al., 2013) (Figure S3A ), we sorted Sca1 + dFBs from all postnatal groups to focus on the dFB population committed to the adipose lineage. Sca1 labeling purity was confirmed by flow cytometry (Figure S3B) , and compared with Sca1 + dFBs, sorted Sca1 À dFBs were confirmed to be unable to differentiate into ADs (Figure S3C) . Because dFBs lost their adipogenic function by 2 months of age ( Figure 2E ), we chose 2 months as the most advanced age group for RNA-seq analyses. Principle-component analysis revealed a distinction in the transcriptomes of dFBs isolated from different age groups. E14 dFBs and 2-month-old Sca1 + dFB samples were clearly separated from P1 Sca1 + dFB samples ( Figure 3A ). Time-course analyses identified seven gene clusters with multiple Gene Ontologies (GOs) undergoing distinct temporal changes . To identify top putative regulators that drive these age-associated changes, we performed Ingenuity Pathway Analysis (IPA) and identified TGF-b signaling as the top activated signaling pathway in 2-month-old Sca1 + dFBs compared with P1 Sca1 + dFBs ( Figure 3C ). IPA also predicted that TGF-b signaling activities were significantly different between dFBs from other age groups and P1 Sca1 + dFBs ( Figures  S3J and S3K ). Consistently, RNA-seq and qRT-PCR analyses ( Figures 3D-3G ) revealed that the expression of the key genes in the TGFBR pathway, including Tgfbr1 or Tgfbr2, Tgfb1 or Tgfb2, and Inhba, was higher in 2-month-old than in P1 Sca1 + dFBs. The expression of several TGF-b pro-fibrotic genes downstream of TGF-b, including Acta2 (coding for alpha smooth muscle actin [SMA]), Ctgf, Spp1, Pai1, Mmp13, Saa3, and Il6, was strongly elevated in 2-month-old cells compared with P1 cells. In contrast, the expression of several pro-adipogenic genes, including Pref1, Pparg, Sca1, Lpl (Gregoire et al., 1998) , and Dcn (a natural inhibitor of TGF-b signaling [Border et al., 1992] ), was suppressed in 2-month-old cells compared with P1 cells. Similar to 2-month-old cells, E14 fibroblasts expressed and secreted significantly higher amounts of Tgfb2 transcript and TGF-b2 protein than neonatal dFBs ( Figures 3E and 3F ). The expression of proadipogenic genes, including Pparg, Sca1, and Dcn, was suppressed in E14 compared with P1 cells, but profibrotic genes, including Acta2 and Spp1, were only moderately elevated in E14 cells, suggesting that the pro-fibrotic effect of TGF-b is preferentially suppressed in embryonic cells. Altogether, these results indicate that TGF-b could play a role in the age-related switch from pro-adipogenic to pro-fibrotic dFBs.
TGF-b2 Drives Loss of Adipogenic-Antimicrobial Function in Neonatal dFBs
To determine whether the presence of TGF-b ligands is functionally relevant, we treated neonatal dFBs with recombinant mouse TGF-b2. Doses as low as 0.1 ng/mL of TGF-b2 potently suppressed the adipogenic function of P1 cells, and at higher doses (3-10 ng/mL) it not only completely abolished adipogenic function but also triggered a fibrotic phenotype characterized by extensive cell striation and spindle-shaped morphology (Figure 4A) . In parallel, the induction of adipocyte marker genes, secretion of cathelicidin and FABP4, and suppression of Col1a1 mRNA upon adipocyte differentiation were inhibited by TGF-b2 ( Figures 4B and 4C ). In undifferentiated P1 dFBs, TGFb2 triggered a dose-dependent decrease in the expression of pro-adipogenic genes (Sca1, Pref1, Pparg1, and Dcn) and an increase in the expression of pro-fibrotic and inflammatory genes (Spp1, Acta2, Mmp13, Pai1, Ctgf, and Il6) ( Figures 4D and 4E ). Similar results were also seen in neonatal dFBs treated with TGF-b1, except that TGF-b1 was three to ten times less potent than TGF-b2 (Figures S4A and S4B) .
To characterize the dynamic interplay between pro-fibrotic and anti-adipogenic functions of TGF-b, we evaluated expression of Sca1 and SMA in PDGFRA Figures 4H and 4I) . Cultured 2-month-old and 1-year-old dFBs strongly resembled neonatal dFBs treated for 2 days with TGFb2 ( Figure 4F ). The antimicrobial activity of differentiating neonatal dFBs against S. aureus was completely suppressed after the addition of TGF-b2 ( Figures 4J, 4K , and S4E). These results demonstrate that TGF-b2 is a potent suppressor of dFBs' capacity to differentiate into ADs and provide antimicrobial activity.
TGF-b Exerts Anti-adipogenic Effects on dFBs by
Activating the TGFBR-SMAD2/3 Pathway To understand the signaling pathway mediating the effect of TGF-b on dFBs, we evaluated downstream signaling molecules of the TGF-b pathway. Phosphoblotting analyses of neonatal dFBs treated with TGF-b2 showed that TGF-b2 induced a transient increase in SMAD2/3 and AKT phosphorylation ( Figure 5A ). To determine the role of SMAD3 and AKT in the effects of TGF-b, we applied small pharmacological inhibitors specific to SMAD3 (SIS3) (Jinnin et al., 2006) , AKT (Wortmannin) (Zhang et al., 2016) , or TGFBR SB431542 (SB) (Inman et al., 2002; Mordasky Markell et al., 2010) . Pretreatment with either SMAD3 or TGFBR inhibitors, but not an AKT inhibitor, rescued TGF-b-driven suppression of Pparg1 and induction of Ctgf mRNA expression (Figure 5B) and restored the adipogenic function and the ability of neonatal dFBs to produce and secrete cathelicidin ( Figures  5C-5D and S5A ). These results demonstrate that TGF-b exerts its pro-fibrotic and anti-adipogenic effects on dFBs via the TGFBR-SMAD2/3 pathway.
Inhibition of TGFBR Function Boosts dFB Adipogenic Potential and Enhances Resistance to Skin Infection
To test the hypothesis that TGF-b2 is responsible for the agedependent loss of adipogenic capacity of dFBs, we treated primary dFBs isolated from mice of various ages with SB in culture for 3 days. Inhibition of TGFBR reversed the loss of Sca1 and gain of SMA observed in PDGFRA + THY1 + dFBs during aging ( Figures 5E-5G ). The age-associated suppression of pro-adipogenic Pparg1 and increased expression of the pro-fibrotic Spp1 were also reversed by SB treatment (Figures 5H and 5I (F) TGF-b2 secretion (pg/mL) in the conditioned medium of dFBs was quantified by ELISA (n = 3 per group).
(G) qRT-PCR analyses validating age-dependent changes in mRNA expression of pro-adipogenic genes (Pref1, Sca1, and Pparg1) or pro-fibrotic genes (Acta2, Ctgf, and Spp1) (n = 3 per group). All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Please also see Figure S3 . Inhibition of TGFBR enabled embryonic and adult dFBs to differentiate into mature adipocytes ( Figure 5J ) and express cathelicidin ( Figure 5K ). Col1a1 expression was also suppressed upon TGFBR inhibition ( Figure S5B) . Furthermore, the antimicrobial potential of the conditioned medium from differentiating embryonic dFBs was enhanced when TGFBR was inhibited ( Figure 5L ).
TGF-b Signaling Is Active in the Dermis and Promotes Loss of Antimicrobial Defense in Mice
To investigate the role of the TGF-b pathway in dFBs in vivo, we examined activation of phosph-SMAD2/3 (pSMAD2/3) and the abundance of TGF-b in mice of various ages. Increased pSMAD2/3 was seen in adult dermis (3 weeks to 2 years of age) compared with neonatal dermis ( Figure 6A ). P1 and 3-week-old skin showed random pSMAD2/3 distribution throughout the dermis, whereas 2-month-to 2-year-old skin showed prominent pSMAD2/3 staining in the dWAT layer ( Figure 6A ). This suggests that pSMAD2/3 signals might be preferentially turned on only in the committed pAds in dWAT during adulthood. Circulating TGF-b2 concentrations in serum were high in neonatal (P1-P7) and young adult mice (3 weeks of age) but then declined progressively with advancing age (2 months to 2 years of age) ( Figure 6B ). In contrast, circulating TGF-b1 concentrations were low in neonates and became elevated from adulthood through aging (Figure 6C ). To determine whether TGF-b might promote dermal fat loss in adulthood, we treated adult mice intradermally with SB for 5 days ( Figure 6D ). SB-treated skin showed notable expansion of the dWAT layer ( Figure 6D ) and higher expression of Camp and Adipoq and lower expression of pro-fibrotic genes (Col1a1 and Ctgf) than non-SB-treated skin ( Figure 6E ). To determine whether these observations could translate into reduced susceptibility to infection in vivo, we administrated SB after infecting 1-year-old adult mouse skin with S. aureus strain USA300 ( Figure 6F ). Treating the infected mice with SB improved resistance to S. aureus skin infection, as shown by a decrease in lesion size and bacterial CFU at the infection edge and in the central area of the lesion (Figures 6F and 6G ). qRT-PCR analyses revealed that SB administration not only increased the expression of pAd-or AD-related genes, including Pdgfra and Camp, but also suppressed expression of the pro-fibrotic gene Spp1 at the infection site ( Figures 6H and S5C) . The reactive adipogenesis responses, including enhanced adipocyte hyperplasia and cathelicidin protein production, upon infection were enhanced in SB-treated mice compared with control mice ( Figure 6I ). In addition, to inhibit TGFBR specifically in dFBs, we generated conditional heterozygous deletion of Tgfbr2 by crossing Tgfbr2 flox/flox mice to Pdgfra-cre (Tgfbr2 flox/+ Pdgfra-cre) mice ( Figure 6J ). No homozygous Tgfbr2 flox/flox Pdgfra-cre offspring were generated despite extensive breeding, and thus experiments were conducted only with heterozygous offspring. dFBs isolated from Tgfbr2 flox/+ Pdgfra-cre mice expressed $50% less Tgfbr2 mRNA than WT dFBs ( Figure S5D ). Tgfbr2 flox/+ Pdgfra-cre dFBs were less responsive to exogenous TGF-b2 treatment, as shown by an impaired induction of profibrotic genes, including Ctgf, Acta2, and Spp1 ( Figures 6K and 6L) . Importantly, when mice were subjected to S. aureus infection, the fibrotic response in the infected skin was significantly reduced in comparison with that of WT controls ( Figure 6M) . Furthermore, more lipid droplets and cathelicidin protein were detected in the infected Tgfbr2 flox/+ Pdgfra-cre dermis than in infected WT controls ( Figure 6N ). Overall bacterial abundance was lower, but not statistically significant, in the infected skin of Tgfbr2 flox/+ Pdgfra-cre mice than in WT controls ( Figures S5E-S5G ), suggesting that heterozygous deletion of Tgfbr2 in Pdgfra + dFBs might not be sufficient to drive a clinical phenotype. These changes demonstrate that TGF-b critically drives age-dependent loss of the innate antimicrobial function of the skin.
TGF-b Promotes Loss of Adipogenic and Antimicrobial Defense Function of Primary Human Dermal Fibroblasts
To determine whether our observations in mice might also be relevant to humans, we evaluated dWAT in human skin samples (Caucasian; non-obese) from neonates (gestational weeks [GW] 29-38), young adults (18-25 years of age), mid-age adults (50-65 years of age), and elderly donors (>75 years of age). Neonatal skin, either preterm (GW 29-32) or full term (GW 38-40), contained a large volume of dWAT and a thin dermis, whereas in adulthood dWAT volume became gradually reduced and was eventually lost in mid-age and elderly skin samples ( Figures 7A and S6A) . A similar trend of dWAT loss during adulthood was also observed in human skin biopsies (Chinese; non-obese) collected from young children (2-6 years of age), young adults (18-25 years of age), and mid-age adults (50-65 years of age) ( Figure S6B ). Similar to that in mouse skin, the mRNA expression of PREF1 or human CAMP was significantly higher in human neonatal skin than in mid-age or elderly skin samples ( Figures 7B and S6C ). Immunostaining of human skin sections for the human cathelicidin peptide LL-37 showed that it was abundantly expressed in neonatal dermal ADs but not in the larger ADs in aged skin (Figure S6D) . dWAT loss in adulthood coincided with an increase in dermal thickness, fibrogenesis (as measured by collagen staining), and COL1A1 mRNA upregulation ( Figures 7A, S6A , and S6E). In elderly human skin, similar to 2-year-old mouse skin, a decrease in dermal thickness, collagen content, and COL1A1 mRNA expression was observed ( Figures 7A, S6A , and S6E), suggesting that prolonged activation of dFBs might eventually lead to loss of cells' pro-fibrogenic function in elderly skin.
To determine whether TGF-b can inhibit adipogenic function of human neonatal dFBs, we differentiated primary neonatal dFBs isolated from five donors into adipocytes with or without TGFBR inhibitor or recombinant TGF-b2. Neonatal dFBs from three donors had high adipogenic capacity and highly expressed CAMP and FABP4 mRNA, both of which could be completely inhibited with TGF-b2 treatment ( Figures S7A and 7C ). In contrast, dFBs isolated from the other two neonatal donors had low basal adipogenic capacity but became highly adipogenic and expressed high CAMP and FABP4 mRNA when TGFBR inhibitor (SB) was added ( Figure S7A and Figure 7C ). Adipogenic capacity positively correlated with PPARG mRNA expression in undifferentiated cells before or after SB treatment ( Figure 7D ). To define the role of TGF-b in controlling the pro-adipogenic and pro-fibrotic functions of human dFBs, we next focused on the neonatal dFBs with low basal adipogenic capacity. Under basal conditions, these cells had a notable fibrotic morphology, characterized by stratification and clustering of cells into aggregates ( Figure 7E ), and this phenotype was further exacerbated upon treatment with TGF-b2, but was potently diminished upon treatment with SB ( Figure 7E ). Flow-cytometry analysis for SMA expression revealed that untreated cells were composed of mixed populations with low, medium, and high expression of SMA, and TGFBR inhibitor treatment shifted these cell populations to mostly an SMA lo state, whereas TGF-b2 treatment shifted them toward mostly an SMA hi state ( Figure 7F ). These cells expressed low basal PPARG mRNA and high ACTA2 and CTGF (fibrotic gene) mRNA, and recombinant TGF-b2 further decreased PPARG and increased ACTA2 and CTGF expression, whereas SB treatment strongly increased PPARG and almost completely suppressed CTGF expression ( Figures S7B and  S7C) . Thus, by default, these cells were weakly adipogenic, and treatment with TGFBR inhibitor restored their adipogenic function and ability to express CAMP ( Figures 7E and S7C ). These results demonstrate that the endogenous TGF-b pathway is constitutively active in neonatal human dFBs with low basal adipogenic capacity and drives them to shift from a pro-adipogenic to a pro-fibrotic phenotype. Furthermore, antimicrobial assays using conditioned medium collected from undifferentiated and differentiated human neonatal dFBs treated with SB demonstrated that only differentiating adipocytes treated with TGFBR inhibitor significantly suppressed growth of two S. aureus strains, SA113 and USA300 ( Figure 7G ). In addition, inhibition of TGFBR in primary adult dFBs isolated from four mid-age adult donors showed a significant decrease in mRNA expression of CTGF and COL1A1 and an increase in PPARG expression (Figure 7H) , suggesting that the TGF-b-mediated switch from proadipogenic to pro-fibrotic also occurs in human adult cells. Together, these results are consistent with observations in mice and demonstrate that TGF-b drives loss of the adipogenic-antimicrobial function of primary human dFBs.
DISCUSSION
Effective defense against S. aureus infections relies on a proper immune response from skin-resident cells, including adipogenic dFBs (Zhang et al., 2015) and lymphoid and myeloid immune cells, such as T lymphocytes, neutrophils, and macrophages (Dillen et al., 2018; Feuerstein et al., 2015; Miller et al., 2006) . It is well established that myeloid-derived innate and adaptive immunity is deficient early in life (Futata et al., 2012; Georgountzou and Papadopoulos, 2017; Shaw et al., 2013) hi dFB population, immature fat, and the adipogenic potential of dFBs became progressively lost as the myeloid immune system matured, suggesting that the latter compensates for the loss of innate immune function of adipogenic dFBs.
To identify the underlying mechanisms for age-dependent changes in adipogenic function of dFBs, we cultured primary dFBs isolated from mouse skin at different ages and observed a drastic pro-adipogenic-to-pro-fibrotic switch that was age All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Scale bars, 100 mm. Please also see Figure S1 . , young adults (18-25 years of age), mid-age adults (50-65 years of age), and elderly adults (>75 years of age). All subjects were white Caucasians (n = 3-6 per age group). dWAT is highlighted by red lines. Scale bars, 100 mm.
(legend continued on next page) dependent: neonatal dFBs were highly adipogenic and potently inhibited bacterial growth, whereas adult cells gained profibrotic features, and both embryonic and adult dFBs had low adipogenic capacities and were not able to control bacterial growth. On the basis of RNA-seq analysis, we hypothesized a key role for TGF-b and confirmed it by reproducing the phenotype of adult or aged cells after treatment of neonatal dFBs with recombinant TGF-b2 and by rescuing loss of function in embryonic, adult, or aged dFBs after administration of a pharmacological inhibitor of TGFBR or via targeted genetic deletion. Administration of TGF-b inhibitor or targeted heterozygous deletion of Tgfbr2 in Pdgfra + dFBs was also effective in vivo at restoring the reactive adipogenesis-antimicrobial defense function of dFBs in adult mice. Although the pro-fibrotic (Lakos et al., 2004) and anti-adipogenic (Choy and Derynck, 2003) functions of TGF-b pathways are already known, our results identify these fundamental functions of TGF-b as a key regulatory mechanism controlling the innate antimicrobial function of dFBs.
In vitro, Tgfb2 was the most abundant TGF-b isoform expressed by dFBs, and its expression correlated with the agerelated loss of adipogenic potential. TGF-b2 was found to be three to ten times more potent than TGF-b1 in triggering the adipogenic-to-pro-fibrotic switch in neonatal dFBs. In vivo, circulating TGF-b2 concentrations in mouse serum were high early in life (from P1 to P3 weeks) and then declined from adulthood through aging, whereas circulating TGF-b1 concentrations were low in neonates and became elevated with advancing age. We posit that a high serum concentration of TGF-b2 early in life might drive the rapid loss of adipogenic function of neonatal dFBs during postnatal development, whereas a decline in TGF-b2 serum concentration later in life might be compensated by rising TGF-b1. TGF-b2 can also be produced by other skin cell types, such as hair follicle keratinocytes and dermal papilla cells (Hibino and Nishiyama, 2004; Soma et al., 2002) , and TGF-b2 could synergize with TGF-b1, which is abundantly produced by immune cells, such as macrophages (Keophiphath et al., 2009 ) and regulatory T cells (Bommireddy and Doetschman, 2007) . Alternatively, endogenous production of TGF-b from adipocytes or surrounding stromal cells could provide a source for autocrine or paracrine suppression of adipocyte progenitors. Future studies will be needed to determine the cellular source of these TGF-b ligands.
Dermal fibroblasts are the major mesenchymal cell type in the skin, and these cells exhibit considerable functional diversity, which was also observed in our culture system. Primary mouse neonatal dFB cultures appeared highly homogeneous (>90% of cells were Sca1 hi SMA lo ), whereas adult dFBs appeared heterogeneous with mixed populations of Sca1 hi-lo and SMA lo-hi cells in culture. The Sca1 lo SMA hi dFBs harbored a myofibroblast-like gene signature (Hinz et al., 2012; Lee et al., 2010) and exhibited higher mRNA expression of pro-fibrotic genes (such as Acta2, Ctgf, and Spp1) and lower expression of pro-adipogenic expression (such as Pref1 and Pparg1) than Sca1 hi SMA lo neonatal dFBs. This adipogenic-to-pro-fibrotic switch by adult cells could be reversed upon inhibition of TGFBR, suggesting that the plasticity between distinct phenotypic subpopulations of dFBs might be controlled by TGF-b. Analogous two-way conversion between myofibroblasts and adipogenic fibroblasts has been reported in several recent studies using genetic lineage-tracing tools in mice. In the mouse model of idiopathic pulmonary fibrosis, lung lipogenic fibroblasts have been observed to differentiate into myofibroblasts during early fibrosis formation, and later, during resolution of fibrosis, the population of newly formed myofibroblasts switches back to lipogenic fibroblasts (El Agha et al., 2017) . In the skin, myofibroblasts that accumulate in the bleomycin-induced mouse model of scleroderma originate from Adipoq-positive intradermal progenitors (Marangoni et al., 2015) . Furthermore, myofibroblasts formed during early skin wound healing give rise to new adipocytes that regenerate de novo during later stages of wound healing around de novo hair follicles (Plikus et al., 2017) . Highly relevant to our work, these studies suggest that the pool of adipogenic fibroblasts in the skin or lung can switch between a profibrotic phenotype (such as myofibroblasts) during injury and a pro-adipogenic phenotype during injury resolution. Our results here suggest that TGF-b might be the key factor that regulates this plasticity between distinct phenotypic subpopulations of dFBs. Future studies are needed to identify the endogenous TGFBR inhibitor that converts pro-fibrotic dFBs to the adipogenic lineage.
In conclusion, these observations have uncovered that an age-dependent activation of the TGF-b pathway attenuates adipogenic function of dermal fibroblasts and promotes a subsequent loss of antimicrobial defense by dermal fat. This work provides insights into how activation of TGF-b negatively affects skin defense against infection and suggests that small molecules that suppress TGFBR might be an effective therapeutic to combat skin infections.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (H) Primary adult human dFBs were isolated from four mid-age donors' back skin. Also shown is qRT-PCR analyses of CTGF, COL1A1, and PPARG1 in adult dFBs treated with vehicle control or TGFBR inhibitor (n = 3 or 4 per group). All error bars indicate mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Please see also Figure S6 and S7. 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Animals and animal care
All animal experiments were approved by the University of California, San Diego (UCSD), Institutional Animal Care and Use committee. C57BL/6 wild-type mice were originally purchased from Jackson laboratory, and were then breeded and maintained in animal facility of UCSD. For aging mouse model, dorsal skin biopsies were collected from C57BL/6 wild-type male mice with various ages (E14, P1, 3W, 2 months and 1 year old). Adipoq-cre mice respectively. Tgfbr2 specific deletion in fibroblasts was achieved by breeding Tgfbr2 flox/flox mice with Pdgfra-cre mice. Probably due to early embryonic lethality, we were not able to get the homozygous deletion of Tgfbr2 in fibroblasts (Tgfbr2 flox/flox ;Pdgfra-cre) over more than one year of breeding, so the heterozygous deletion of Tgfbr2 in fibroblasts (Tgfbr2 flox/+ ; Pdgfra-cre) was used instead as the Tgfbr2 heterozygous deletion model to study the role of TGFBR pathway in the infection triggered dermal adipogenesis-antimicrobial response. Dorsal skin biopsies around the same area were collected from mice with various ages for analysis to control the consistency of the tissue site collected over the whole lifetime of the mouse
Mouse model of S. aureus skin infection
Skin infection experiments were done as described before (Zhang et al., 2015) . Staphylococcus aureus strain USA300 (MRSA) was used for in vivo infection. In brief, the backs of sex-matched and age-matched adult wild-type or indicated strain of mutant mice were shaved and hair removed by chemical depilation (Nair) then injected subcutaneously with 100 mL of a mid-logarithmic growth phase of S. aureus (1x 10 7 CFU of bacteria) in PBS. Mice were sacrificed after day 3 and skin biopsy covering the infection area was harvested. Skin biopsies were homogenized in 1 mL Trizol (for RNA) or PBS (for CFU counting) with 2 mm zirconia beads in a mini-bead beater 16 (Biospect, Bartlesville, OK). To count CFU, homogenized skin samples were serially diluted, plated onto Tryptic Soy Agar, and enumerated after 18 hr to quantify the CFU per gram of tissue. For administration of TGFBR inhibitor, SB431542 (0.125 mg in 100uL of 2% DMSO + 30% PEG300 + PBS) or vehicle control was injected intradermally within the infection site at 24 hr and 48 hr post infection and skin biopsies were collected at day 3 post infection for RNA extraction or CFU count as described above. For all animal studies, animals were randomly selected without formal pre-randomization and quantitative measurements were done without the opportunity for bias.
METHOD DETAILS
Chemicals, antibodies and dyes IBMX (3-Isobutyl-1-methylxanthine), dexamethasone, indomethacin, and recombinant human insulin were purchased from SigmaAldaich (St. Louis, MO). SB431542 and SIS3 were purchased from Selleckchem (Houston, TX). Wortmannin was purchased from EMD Millipore (Billerica, MA). Rabbit anti-CRAMP and rabbit anti-LL-37 antibodies were made from our lab as described previously (Zhang et al., 2015; Zhang et al., 2016) ; goat anti-COLIV, mouse anti-FABP4 and rabbit anti-SMAD2/3 antibodies are from Abcam (Cambridge, MA); Lipid dye bodipy is from Molecular Probes (Eugene, OR). Rabbit anti-Phospho-SMAD2, 3, rabbit anti-phospho-AKT antibody and mouse anti-AKT antibody were purchased from Cell Signaling (Danvers, MA). Recombinant mouse TGFb1 and TGFb2 were purchased from R&D Systems (Minneapolis, MN).
Human skin sample collection Fresh adult human (Caucasian) full thickness skin biopsies, from the back of healthy and non-obese male donors between 18$90 years of age, were collected by the Dermatology clinics, University of California San Diego. Fresh adult human (Chinese) full thickness skin biopsies were collected by Hospital for skin disease, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College. All sample acquisitions, were approved and regulated by the University of California San Diego Institutional Review Board (reference number 140144) or by Institute of Dermatology, Chinese Academy of Medical Science Medical Ethics Committee (reference number 2012003). The informed consent was obtained from all subjects prior to skin biopsies. Fresh neonatal full thickness skin samples, from the back of neonatal donors, were obtained from the international institute for advancement of Medicine (IIAM; Exton, PA). The informed consent was obtained from parent of neonatal donor prior to skin collection. All human biopsies were taken from the back skin, where it is relatively protected from sun exposure compared to other regions such as face and neck of the body. Upon collection, these samples were directly fixed with PFA then proceed for either paraffin embedding or OCT embedding for histological or immunofluorescent analyses.
Histology, collagen trichrome staining and immunohistochemistry (IHC) Paraffin embedding and sectioning was performed by the Moores cancer center histology core at UCSD. For OCT embedding, tissue biopsies were first fixed with 4% PFA for 2 hours then cryoprotected by sucrose for 48 hours prior to being embedded in OCT compound and stored in À80 C. Histological analysis was performed using either paraffin sections or frozen sections by Hematoxylin-Eosin (H&E) staining. Collagen was stained by the Richard-Allan Scientific Gomori Trichrome green collagen staining kit (ThermoFisher Scientific, Waltham, MA, USA). Elastic staining (Thermo Fisher Scientific, Waltham, MA, USA) and hydroxyproline assay (BioVision) were performed on human or mouse tissues according to manufacturer's instructions. For IHC, fixed and permeabilized tissue sections were blocked with Image-iT FX reagent (invitrogen) before incubating with primary antibodies followed by appropriate 488-or Cy3-coupled secondary antibodies. Nuclei were counter-stained with DAPI. All images were taken with an Olympus BX41 microscope (widefield) or Zeiss LSM510 confocal microscope as indicated.
Primary dermal fibroblast isolation and culture For neonatal mouse dorsal skin, epidermis was first removed from the dermis by overnight dispase digestion as described before, and for adult skin hair was first removed by clipper then cut into 5mm wide strips prior to dispase digestion. The dermis was then cut into small pieces ($1 mm) by scalpel then digested with 2.5 mg/mL Collagenase D and 30 ng/mL DNase1 for 2 hours at 37 C with constant rocking to release dermal fibroblasts. Cells mixture was then filtered through 30 mm filter into single cell suspension then treated with red blood cell lysis buffer. Isolated dermal fibroblasts were cultured in growth medium (DMEM supplemented with 10% FBS, glutamax and antibiotics-antimicotics) in a humidified incubator at 5% CO2 and 37 C under sterile conditions. Fresh medium was replenished daily to remove debris or dead cells. Primary cells were then trypsinized within 3 days and replated at 5 3 10 4 /mL for in vitro assays, and only passage 1 cells were used for experiment. To induce adipocyte differentiation, two day post-confluent dFB were switched to adipocyte differentiation medium containing 2 mM Dexamethasone, 250 mM IBMX, 200 mM Indomethacin and 10 mg/mL recombinant human insulin. Fresh differentiation medium was changed at day 2, 4, and 7 during the differentiation time course.
Flow cytometry and analysis (FACS)
FACS analysis of primary dermal fibroblasts was modified from previously reported method for adipogenic fibroblasts (Chia et al., 2016; Rivera-Gonzalez et al., 2016) . Briefly, freshly isolated dFB from mouse skin or primary cultured of dFB first were stained with zombie violet viability dye (BioLegend, 423114) to stain dead cells. Cells were then blocked with anti-mouse CD16/32 (eBioscience, 14016185), followed by staining with an antibody cocktails containing PECy7-CD45 (BioLegend, 147704), PerCPCy5.5-CD31 (BioLegend, 102522), PE-THY1 (BioLegend, 105308), APC-PDGFRA (CD140a) (eBioscience, 17140181) and BV605-Sca1 (BioLegend, 108133). Stained cells were then fixed and permeabilized using the intracellular fixation and permeabilization buffer set (eBioscience), then intracellular SMA was stained by AF488-SMA (eBioscience, 53976082). For FACS staining of T cell populations, cells were stained with an antibody cocktail including APC-CD4 (Biolegend, 100516), BV510-CD8a (Biolegend, 100752), APC-Cy7-TCRb (Biolegend, , , and PerCP-Cy5.5-CD45.2 (Biolegend, 109828). For FACS staining of other myeloid immune cell panel, cells were stained with an antibody cocktail including PECy7-CD11B (BioLegend, 101216), FITC-Ly6G (eBioscience, 11593182), PE-F4/80 (eBioscience,12480182), APC-CD11C (BioLegend, 117310), AF700-MHCII and (eBioscience, 56532182) FACS analysis for protein expression of each cell marker was performed by the BD FACSCanto RUO machine and analyzed by FlowJo V10 software. Dead cells stained positive with zombie violet dye were excluded from the analyses.
Reverse transcription-quantitative PCR (RTqPCR) analyses Total cellular RNA was extracted using the PureLink RNA isolation kit with RNase-free DNase1 digestion to remove genomic DNA contamination (QIAGEN) and 500 ng of RNA was reverse transcribed to cDNA using iScript cDNA synthesis kit (Bio-rad). Quantitative, real-time PCR was performed on the CFX96 real time system (Bio-rad) using SYBR Green Mix (Bimake, Houston, Tx). All of the primers used with SYBR green were designed to span at least one exon to minimize the possibility of nonspecific amplification from the genomic DNA. The expression of Tbp gene (TATA-Box Binding Protein) was used as a house keeping gene to normalize data for the expression of mouse genes, and HPRT was used as a house keeping gene for the expression of human genes. Specific primer sequences are shown in Table S1 (mouse genes) and Table S2 (human genes).
Immunoblotting analyses 10ul of cell medium was separated on a 10%-20% Tris-Tricine precast gel (Biorad), transferred to PVDF membrane (Biorad), followed by immunoblotting using indicated primary antibodies followed by fluorescent secondary antibodies (LICOR) and imaging using fluorescent Odyssey System (LICOR).
TGFb1 and TGFb2 ELISA Mouse TGFb1 or TGFb2 ELISA Kit was purchased from R&D Systems (Minneapolis, MN) and TGFb1 orTGFb2 concentrations in conditioned medium from primary mouse dermal fibroblasts or mouse serum were determined according to manufacturer's instruction.
In vitro bacterial killing assay Antibiotic free and phenol-red free conditioned medium was collected from differentiating dermal fibroblasts as described before (Zhang et al., 2015) . The conditioned medium (100 mL) was then mixed with 10 5 /ml CFU (colony forming unit) of indicated bacterial strain in 96 well tissue culture microtiter plates and incubated at 37 C for 10 $48 hr prior to plating for CFU counting. The optical density at 595 nm (OD595) was also measured every 2$4 hours by a spectrometer.
Sample preparation for RNA-seq Primary dermal fibroblasts, isolated from dorsal skin of mouse at E14, E17, P1, 3 weeks and 2 months of age, were harvested at the first passage. To enrich fibroblasts that have committed to adipocyte lineage, Sca1+ dFB were purified from P1, 3 week and 2 month dFB using the anti-Sca1 microbeads kit and MACS columns and separators (Miltenyi Biotec, San Diego, CA). Purity of cells from each age group was greater than 90% as confirmed by FACS analyses. Total cellular RNA was extracted using the PureLink RNA isolation kit with DNase1 digestion to remove genomic DNA contamination (Life Technologies) and 10 ng total RNA (n = 3 for each age group) was used for SMART-seq2.
SMART-seq2
SMART-seq2 was performed as previously described with minor. Briefly, 10 ng total RNA (RIN > 9.6) was reversed transcribed using Super Script II (Invitrogen). cDNA was pre-amplified for 10 cycles using high fidelity KAPA HiFi HotStart Ready Mix (Kapa Biosystems). Pre-amplified cDNAs were cleaned with AMPure XP beads (Beckman Coulter) at a 1:1 ratio and eluted with elution buffer (QIAGEN). Tn5-mediated tagmentation was performed on 18 ng total cDNA using the Nextera DNA Sample Preparation Kit (Illumina) at 55 C for 5 minutes and deactivated with PM buffer (QIAGEN). Adaptor-ligated fragments were amplified for 8 continuous cycles using universal Ad1 and unique Ad2.xx barcodes (IDT). Amplified PCR fragments were purified with AMPure XP beads as suggested (Beckman Coulter). Size selected libraries were quantified using Qubit (Thermo), loaded on a High-Sensitivity DNA chip for quality control (Agilent), and quantified using KAPA for Illumina Sequencing Platforms (Illumina). Libraries were multiplexed and sequenced as paired-end, 43 bps on a NextSeq 500 Illumina Sequencing Platform (Illumina) (Cluster density = 252K/mm2, Clusters PF = 78.8%, Q30 = 90.7%).
Transcript alignment, quantification and filtering Paired-end reads were aligned to the mouse genome (mm10/gencode.vM4) with bowtie (version 1.0.0) and quantified using the RNAseq by Expectation-Maximization algorithm (RSEM) (version 1.2.12) with the following standard parameters: rsem-calculate-expression -p $CORES-paired-end. Samples displaying > 12,000,000 aligned reads and > 77% alignment were considered for downstream analyses. Samples were filtered and only protein-coding genes and lncRNAs expressed at minimum 1 TPM in at least one sample in all biological replicates were considered for downstream analyses.
SMART-seq2 and IPA analyses Differential expression dynamics across E14, E17, P1-Sca1
+ samples was identified using the single-time series, two-step regression model algorithm Next maSigPro using with the following parameters under the T.Fit, get.siggenes and see.genes functions: alfa = 0. 01, vars = ''all,'' rsq = 0.7, k = 7 . Principle component analyses were performed using the R ggbiplot package. Pathway and upstream regulator analyses were performed by Ingenuity pathway analysis (IPA) from QIAGEN.
QUANTIFICATION AND STATISTICAL ANALYSIS
Experiments were repeated at least 3 times with similar results. Statistical significance was determined using Student's unpaired two-tailed t test, or one way ANOVA multiple comparison test as indicated in the legend (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
DATA AND SOFTWARE AVAILABILITY
RNA-seq data of cultured dermal fibroblasts reported in this paper has been deposited to NCBI Gene Expression Omnibus (GEO), GEO: GSE121460.
